| SEC Form 4 |   |
|------------|---|
| FORM       | 4 |

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See |
|---|
| Instruction 1(b).   |

#### obligations may continue. See Instruction 1(b).

| 1 | Check this box to indicate that a<br>transaction was made pursuant to a<br>contract, instruction or written plan<br>for the purchase or sale of equity<br>securities of the issuer that is<br>intended to earlief, the offermative |
|---|--|
|   | intended to satisfy the affirmative<br>defense conditions of Rule 10b5-<br>1(c). See Instruction 10.   |

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL |           |  |  |  |  |
|--------------|-----------|--|--|--|--|
| MB Number:   | 3235-0287 |  |  |  |  |

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

| 1. Name and Address of Reporting Person <sup>*</sup><br><u>HIGH SUSANNA GATTI</u> |               |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Dyne Therapeutics</u> , Inc. [ DYN ] |                   | tionship of Reporting Per<br>all applicable)<br>Director                                  | 10% Owner<br>Other (specify<br>below) |  |
|---|---------------|----------------|---|-------------------|---|---------------------------------------|--|
| (Last) (First) (Middle)<br>C/O DYNE THERAPEUTICS, INC.<br>1560 TRAPELO ROAD       |               | ( )            | 3. Date of Earliest Transaction (Month/Day/Year)<br>09/18/2024                                |                   | Officer (give title<br>below)<br>Chief Operating  |                                       |  |
| (Street)<br>WALTHAM<br>(City)   | MA<br>(State) | 02451<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                      | 6. Indiv<br>Line) | vidual or Joint/Group Filin<br>Form filed by One Rep<br>Form filed by More that<br>Person | orting Person                         |  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | Execution Date, |                         |   |        | Date,<br>Code (Instr. Disposed Of (D) (Instr. 3, 4 and 5) Securities Form:   y/Year) 8) Owned Following (I) (Instr. 3, 4 and 5) Instruction Instruction (D) or |                               | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |            |
|---------------------------------|--|-----------------|-------------------------|---|--------|--|-------------------------------|---|---|------------|
|                                 |  |                 | Code                    | v | Amount | (A) or<br>(D)  | Price                         | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                    |   | (Instr. 4) |
| Common Stock                    | 09/18/2024                                 |                 | <b>S</b> <sup>(1)</sup> |   | 4,340  | D  | \$34.41(2)                    | 136,272 <sup>(3)</sup>  | D   |            |
| Common Stock                    | 09/18/2024                                 |                 | S <sup>(4)</sup>        |   | 4,636  | D  | <b>\$34.41</b> <sup>(2)</sup> | 131,636 <sup>(3)</sup>  | D   |            |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |     | of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4 |  | Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4 |  | Expiration Date<br>(Month/Day/Year) |  | Expiration Date<br>(Month/Day/Year)<br>urities<br>uired<br>or<br>iosed<br>0)<br>0,<br>r. 3, 4 |  | Amount of |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-----|--|--|--|--|-------------------------------------|--|---|--|-----------|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D) | Date Expiration<br>Exercisable Date  |  | Title  | Amount<br>or<br>Number<br>of<br>Shares |                                     |  |   |  |           |  |   |  |  |  |

Explanation of Responses:

1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$34.09 to \$34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

3. Includes 114,453 unvested RSUs.

4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.

| /s/ Richard Scalzo, Attorney- | 00/1        |
|-------------------------------|-------------|
| in-Fact                       | <u>09/1</u> |

9/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.